Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Andres Zuleta: Evaluating the RISE UP Trial Results on Mitapivat for Sickle Cell Disease
Nov 20, 2026, 00:02

Andres Zuleta: Evaluating the RISE UP Trial Results on Mitapivat for Sickle Cell Disease

Andres Zuleta, Founder of Thrivemed, Medical Director PMC at Benchmark Hospitalists and Intensivists, shared a post on LinkedIn:

“207 people with sickle cell disease: a twice-daily pill raised hemoglobin in 41%, versus 3% on placebo.

But yearly pain crises, 2.6 vs 3.1, were not significantly different.

As a physician, I want patients to hear both results, the goal it met and the one it missed.

RISE UP (The Lancet, 2026) was a phase 3, double-blind trial at 69 sites in 15 countries.

Mitapivat activates pyruvate kinase in red cells, raising ATP and lowering 2,3-DPG, which may keep hemoglobin oxygenated longer and reduce sickling. Patients older than 16 with anemia and recurrent pain crises were randomized 2:1 to 100 mg twice daily or placebo.

What I take from it as a physician:

  • Hemoglobin response (at least 1 g/dL average rise, weeks 24-52): 56 of 138 vs 2 of 69.
  • Serious adverse events were 20% vs 29%; one was judged treatment related.
  • Pain crises did not drop significantly, and the trial was funded by the drug’s maker, Agios.

Comment and I’ll send you the paper.

Hematologists: how much weight do you give a hemoglobin response when pain crises don’t change?”

Andres Zuleta

Stay updated with Hemostasis Today.